Search Results
Your search for s matches 6982 pages
Showing 851 - 900Inspired by the TV Show M*A*S*H, Lori Wilson, MD, FACS, Achieves Many Firsts as a Leader in Oncology
Lori Wilson, MD, FACS, Chief of Surgical Oncology, Associate Dean of Faculty Development and Diversity, and former Program Director of the General Surgical Residency at Howard University Hospital, is the first woman to hold the position of Division Chief as well as the first tenured Professor of...
New Study: Patients Report Increased Likelihood to Enroll in Decentralized Clinical Trials
A new article published by Adams et al in JAMA Network Open details the potential benefits of using technology to increase patient participation in cancer clinical trials. In a survey of nearly 1,200 patients with cancer and survivors, more than 80% said they would be willing to use remote...
Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer
New drugs for HER2-positive breast cancer are able to overcome some of the obstacles that have made brain metastases challenging to treat, according to Mark Pegram, MD, the Susy Yuan-Huey Hung Professor of Oncology at Stanford University School of Medicine in California, who described the promising ...
Study Finds COVID-19 Vaccines Are Safe for Patients Treated With Immune Checkpoint Inhibitors for Lung Cancer
Patients with cancer have received priority status to receive COVID-19 vaccinations, but limited data are available regarding the safety and efficacy of the vaccines for patients treated with immune checkpoint inhibitors for lung cancer. Now, a new study published by Hibino et al in the Journal of...
Chemicals in Personal Care Products May Increase Breast Cancer Risk in Black Women
The group of compounds called parabens, which are found in widely used hair and personal care products, may increase breast cancer risk in Black women—more so than in White women—according to a study presented at ENDO 2022, the Endocrine Society’s Annual Meeting. One in eight women in the United...
History of Radiation Oncology in the United States
Radiation therapy has long been one of the three pillars of cancer therapy—surgery, chemotherapy, and radiotherapy—only recently joined by what is widely considered a fourth pillar, immunotherapy. In part 1 of this two-part report, we trace the beginnings of radiation oncology in the United...
ARIEL4 Confirms Rucaparib’s Efficacy in Recurrent, BRCA-Mutated Ovarian Cancer: Does It Tell Us Anything New?
In March 2022, Kristeleit et al reported the results of the ARIEL4 trial1 of rucaparib in relapsed BRCA-mutant ovarian cancer in The Lancet Oncology (summarized in this issue of The ASCO Post) and are to be congratulated on this accomplishment. This report, along with the almost simultaneous...
Dabrafenib/Trametinib Combination Receives FDA Approval for BRAF V600E–Mutated Solid Tumors
On June 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval for dabrafenib (Tafinlar) plus trametinib (Mekinist) for the treatment of adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors with a BRAF V600E mutation whose disease...
Cancer and War in Ukraine: How the World Can Help Win This Battle
In Ukraine, with a population of about 44 million, there are more than 1.3 million patients with cancer. Approximately 160,000 new cases of cancer are diagnosed each year.1 In almost every region, there are local cancer centers; specialized oncologic centers are located in large cities. In Kyiv,...
Invest in the Unexpected: Basic Research Enterprise Needs Adequate Funding to Foster Treatment Innovation
The National Institutes of Health (NIH) now stands as the largest single public funder of biomedical research in the world.1 The FY2022 Consolidated Appropriations Act (H.R. 2471), signed into law in March, increases biomedical research funding by nearly 5%, and it provides a total of $45 billion...
Interventions Needed to Improve Data Collection on Sexual Orientation and Gender Identity in Oncology Practice, Survey Finds
Recently, a new ASCO study,1 published in JCO Oncology Practice, found that among respondents participating in the survey, most oncology practices do not systematically collect data related to sexual orientation and gender identity (SOGI). The study points to the need to increase understanding...
Expert Point of View: Thomas Seufferlein, MD
Thomas Seufferlein, MD, Professor of Medicine at Ulm University Hospital in Germany, found the data from the NOTABLE trial1 encouraging and “clinically interesting.” However, he suggested the study’s design did not allow the EGFR inhibitor to be optimally tested. The NOTABLE trial is based on a...
NOTABLE Trial: Survival in Pancreatic KRAS Wild-Type Cancer Improved With Addition of Nimotuzumab to Gemcitabine
In patients with locally advanced or metastatic pancreatic cancer and KRAS wild-type tumors, novel treatment with the monoclonal antibody nimotuzumab, which targets the epidermal growth factor receptor (EGFR), plus gemcitabine significantly improved overall survival and other outcomes over...
TROPiCS-02 Sacituzumab Govitecan Effective in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
For advanced breast cancer that is hormone receptor–positive and HER2-negative, sacituzumab govitecan-hziy significantly reduced the risk of disease progression by 34% over physician’s choice of treatment, based on the results of the phase III TROPiCS-02 trial.1 The heavily pretreated patients in...
Expert Point of View: Kimmie Ng, MD, MPH
The study’s invited discussant was Kimmie Ng, MD, MPH, Associate Professor of Medicine at Harvard Medical School and Co-Director of the Colon and Rectal Cancer Center at Dana-Farber Cancer Institute, Boston. “Neoadjuvant dostarlimab-gxly for 6 months represents a promising new treatment for...
DESTINY-Breast04 Trial: T-DXd Significantly Improves Survival in Patients With HER2-Low Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) doubled progression-free survival compared with chemotherapy alone in patients with “HER2-low” metastatic breast cancer—ie, patients with low levels of HER2 expression. The agent also extended overall survival for patients with low ...
William Catalona, MD, on the Evolution of Views Regarding Active Surveillance in Men With Low-Risk Prostate Cancer
William Catalona, MD, Professor of Urology at Northwestern University’s Feinberg School of Medicine, and past Principal Investigator on the Northwestern-based prostate SPORE, explained the evolution of his views regarding active surveillance in men with low-risk prostate cancer. Although...
Looking Back at Telemedicine During the COVID-19 Era: Lessons Learned and Disparities Identified
Telemedicine stepped up to the plate when the COVID-19 pandemic swept the globe. Oncology providers—and practitioners in all specialties—had to rapidly adapt to a telemedicine format when face-to-face visits were severely limited. This scenario had its benefits for both patients and providers (and...
Relapsed/Refractory Hodgkin Lymphoma
This is Part 4 of Updates in Lymphoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alison J. Moskowitz, Andrew M. Evens, and Ann S. LaCasce discuss the management of relapsed/refractory Hodgkin lymphoma. The patient is a...
Hodgkin Lymphoma in Patients Age ≥ 60 Years
This is Part 3 of Updates in Lymphoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alison J. Moskowitz, Andrew M. Evens, and Ann S. LaCasce discuss Hodgkin lymphoma in patients age ≥ 60 years. The patient is a 65-year-old man...
Bulky Early-Stage Hodgkin Lymphoma
This is Part 2 of Updates in Lymphoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alison J. Moskowitz, Andrew M. Evens, and Ann S. LaCasce discuss the management of bulky early-stage Hodgkin lymphoma. The patient is a...
Advanced-Stage Hodgkin Lymphoma
This is Part 1 of Updates in Lymphoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alison J. Moskowitz, Andrew M. Evens, and Ann S. LaCasce discuss the management of advanced-stage Hodgkin lymphoma. The patient is a...
Eunice S. Wang, MD, on AML: Long-Term Results With Crenolanib Plus Chemotherapy
Eunice S. Wang, MD, of Roswell Park Comprehensive Cancer Center, discusses long-term phase II findings of a trial evaluating crenolanib plus chemotherapy in newly diagnosed adults with FLT3-mutant acute myeloid leukemia. The study showed a composite complete remission rate of 86%. With a median...
Cleveland Clinic Announces New Appointments to Oncology Staff
The Cleveland Clinic-Taussig Cancer Center recently announced two new appointments and updates to the Center’s staff and faculty. Sophia Balderman, MD, has joined the leukemia group at Taussig Cancer Institute. Prior to her new role, Dr. Balderman was Assistant Professor in the Department of...
Researcher Xiao-Jing Wang, MD, PhD, Joins UC Davis Cancer Center’s Leadership Team
Xiao-Jing Wang, MD, PhD, assumed the role of Chief Science Officer and Associate Director for Basic Science for the UC Davis Comprehensive Cancer Center in Davis, California. She is also Associate Director for Basic Science. Dr. Wang comes to UC Davis from the University of Colorado Anschutz...
Emily Whitehead, First Pediatric Patient to Receive CAR T-Cell Therapy, Celebrates Remission 10 Years Later
Tom and Kari Whitehead came to Children’s Hospital of Philadelphia (CHOP) 10 years ago looking for a miracle. Their 6-year-old daughter, Emily, had relapsed in her battle with acute lymphoblastic leukemia (ALL), after many months of unsuccessful chemotherapy and a disease that had progressed so...
Expert Point of View: Mafalda Oliveira, MD, PhD
The invited discussant of the TUXEDO-1 trial1 was Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona. Dr. Oliveira noted that 40% of the 15 patients in TUXEDO-1 had symptomatic disease, and 60% had central nervous system metastases...
Annual Meeting of the Moroccan Cancer Society: An Opportunity for Young Cancer Researchers to Evolve
The Moroccan Cancer Society (MCS; Société Marocaine de Cancérologie/https://smc.ma) was created in 1992 by a group of Moroccan medical and radiation oncologists, surgeons, and pathologists who had led the field in the 1980s. To date, this scientific society has more than 350 members practicing in...
T-DXd Shows Efficacy Against Active Brain Metastases in HER2-Positive Breast Cancer
In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...
Cemiplimab-rwlc Improves Overall Survival vs Chemotherapy in Recurrent Cervical Cancer After First-Line Platinum-Based Chemotherapy
As reported in The New England Journal of Medicine by Krishnansu S. Tewari, MD, of the Division of Gynecologic Oncology, University of California, Irvine, and colleagues, the phase III EMPOWER-Cervical1/GOG-3016/ENGOT-cx9 trial has shown improved overall survival with cemiplimab-rwlc vs...
Expert Point of View: Mafalda Oliveira, MD, PhD
The invited discussant of the BEGONIA trial,1 Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, called the activity of the combination of durvalumab and datopotamab deruxtecan (Dato-DXd) “notable,” with a 74% response rate overall,...
DESTINY-Breast03: Should Trastuzumab Deruxtecan Be the Preferred Second-Line Regimen in HER2-Positive Metastatic Breast Cancer?
Since the introduction of trastuzumab in the late 1990s, overall survival for patients with HER2-positive metastatic breast cancer has substantially improved. Median overall survival in the pivotal first-line trial was only 20.3 months in the chemotherapy arm, and 25.1 months in the...
MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting
In an updated analysis of the phase III MONALEESA-3 trial, which included postmenopausal patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, first-line treatment with ribociclib plus fulvestrant added nearly 16 months of overall survival time vs fulvestrant...
Sue S. Yom, MD, PhD, on Oropharyngeal Cancer and the Feasibility of a Cell-Free DNA Plasma Assay
Sue S. Yom, MD, PhD, of the University of California, San Francisco, discusses a translational analysis from the NRG-HN002 study. This phase II trial established the feasibility of the tumor tissue–modified viral (TTMV) human papillomavirus DNA assay in clinical trial specimens. The goal is to use...
Jenny S. Guadamuz, PhD, on Racial and Socioeconomic Disparities in Telemedicine Use Among U.S. Patients With Cancer During the COVID-19 Pandemic
Jenny S. Guadamuz, PhD, of Flatiron Health, discusses the use of telemedicine services in community oncology clinics for patients initiating treatments for 21 common cancers during the COVID-19 pandemic. Black, uninsured, non-urban, and less affluent patients were less likely to use telemedicine...
Alicia K. Morgans, MD, MPH, and Michael S. Hofman, MBBS, on Prostate Cancer: New Data on Lutetium-177–PSMA-617 (LuPSMA) vs Cabazitaxel
Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Michael S. Hofman, MBBS, of Peter MacCallum Cancer Centre, University of Melbourne, discuss follow-up results on LuPSMA vs cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel...
Lisa A. Carey, MD, and Hope S. Rugo, MD, on Advanced Breast Cancer: New Data on Sacituzumab Govitecan-hziy vs Treatment of Physician’s Choice
Lisa A. Carey, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discuss phase III results from the TROPiCS-02 trial. This study showed that...
Albert Einstein Cancer Center Announces New Appointments to Key Leadership Positions
The Albert Einstein Cancer Center (AECC) in Bronx, New York, has announced the appointment of three faculty members to key leadership positions, reflecting the center’s commitment to basic science, translational, and clinical research and its core principles of diversity, equity, and inclusion. New ...
Turning Point
On a cool, gray November morning, I took the call from a walk-in doctor about Carla, a 26-year-old woman with progressive lymphadenopathy who was refusing investigations because of severe needle phobia. Carla was willing to meet with me to discuss treatment options for a suspected diagnosis of...
NCI Launches Program to Offer Molecular Characterization of Childhood Cancers
In support of President Biden’s Cancer Moonshot goal of fostering data sharing in cancer research, the National Cancer Institute (NCI), which is part of the National Institutes of Health, has launched the Molecular Characterization Initiative for pediatric tumors. This program offers tumor...
ASCO Leadership for 2022–2023 Term Announced
Individuals elected to ASCO leadership for the 2022–2023 term were announced earlier in the year. Lynn M. Schuchter, MD, FASCO, was elected to serve as the Society’s President beginning in June 2023. Dr. Schuchter will take office as President-Elect immediately after the 2022 ASCO Annual Meeting in ...
Missed Opportunities in Geriatric Oncology Research
The underrepresentation of older patients (≥ 65 years) in clinical trials has been well documented for more than 20 years. This has been an issue at all phases of drug development, including pivotal trials for drug approvals,1 despite the fact that many of these new therapeutics will primarily be...
From the Segregated Tennis Courts of Washington, DC, to a Leadership Role in Surgical Oncology
Success in tennis demands precision timing, extraordinary hand-eye dexterity, and commanding mental and physical vigor. According to Harold P. Freeman, MD, the discipline and skills he learned on the tennis courts at an early age stood him in good stead during his remarkable life’s journey. “My...
ASCO Honors 2022 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2022 ASCO Annual Meeting in Chicago. “This year’s Special...
Multiple Myeloma: Treatment Conundrums
The availability of numerous new agents for treating multiple myeloma has created some “conundrums” for clinicians, said Sergio Giralt, MD, Deputy Head of the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center and the Melvin Berlin Family Chair in Myeloma Research and...
Use of Telemedicine for Cancer Care Increased During the COVID-19 Pandemic but Varied by Race, Socioeconomic Status, and Other Factors
With the rapid acceleration of the spread of the COVID-19 virus in the United States in March 2020, telemedicine visits became more common for cancer care. However, in an evaluation of telemedicine inequities among patients with 21 common cancers, there were distinctly lower levels of telemedicine...
ASCO Guideline Rapid Update Addresses the Use of Neoadjuvant Pembrolizumab in High-Risk Early-Stage Triple-Negative Breast Cancer
A rapid update to the ASCO Guideline on neoadjuvant therapy for breast cancer adds a recommendation on the use of pembrolizumab in patients with high-risk early-stage triple-negative breast cancer.1 The update follows a recent analysis from the randomized phase III KEYNOTE-522 trial that showed a...
CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy Improves Event-Free Survival Over Chemotherapy Alone in Resectable NSCLC
The combination of neoadjuvant nivolumab plus chemotherapy achieved statistically significant and clinically meaningful improvement in event-free survival vs chemotherapy alone (P = .005) in patients with resectable non–small cell lung cancer (NSCLC, stage IB–IIIA), according to the results of the ...
Children’s Hospital of Philadelphia Establishes the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy
Children’s Hospital of Philadelphia (CHOP) announced it has received a significant gift from Susan and Steve Kelly, local philanthropists and long-time supporters of CHOP, to establish the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy. The new Center, led by Stephan Grupp, MD, PhD,...
Understanding Oncologists’ Perceptions About Palliative Care and the Barriers Preventing Its Use
Despite studies showing the benefits of early palliative care in improving the quality of life of patients with advanced cancer (including reducing symptoms of depression),1 a recent survey of oncologists found there is broad variation in the appropriate utilization of this care.2 Conducted by...
